BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 26517533)

  • 1. Optimal management of low-risk gestational trophoblastic neoplasia.
    Goldstein DP; Berkowitz RS; Horowitz NS
    Expert Rev Anticancer Ther; 2015; 15(11):1293-304. PubMed ID: 26517533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Lurain JR; Chapman-Davis E; Hoekstra AV; Schink JC
    J Reprod Med; 2012; 57(7-8):283-7. PubMed ID: 22838241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France.
    Descargues P; Hajri T; Massardier J; Lotz JP; Devouassoux-Shisheboran M; Allias Montmayeur F; You B; Golfier F; Bolze PA
    Am J Obstet Gynecol; 2021 Oct; 225(4):401.e1-401.e9. PubMed ID: 34019886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
    Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
    Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
    Rattanaburi A; Boonyapipat S; Supasinth Y
    Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
    Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG
    Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
    Song SQ; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.
    Mao Y; Wan X; Lv W; Xie X
    Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010.
    Agarwal R; Alifrangis C; Everard J; Savage PM; Short D; Tidy J; Fisher RA; Sebire NJ; Harvey R; Hancock BW; Coleman RE; Seckl MJ
    J Reprod Med; 2014; 59(1-2):7-12. PubMed ID: 24597279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
    Braga A; Paiva G; Ghorani E; Freitas F; Velarde LGC; Kaur B; Unsworth N; Lozano-Kuehne J; Dos Santos Esteves APV; Rezende Filho J; Amim J; Aguiar X; Sarwar N; Elias KM; Horowitz NS; Berkowitz RS; Seckl MJ
    Lancet Oncol; 2021 Aug; 22(8):1188-1198. PubMed ID: 34181884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
    Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
    Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
    Cagayan MS
    J Reprod Med; 2012; 57(5-6):231-6. PubMed ID: 22696818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
    Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
    J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study.
    Jareemit N; Therasakvichya S; Freitas F; Paiva G; Ramírez LAC; Berkowitz RS; Horowitz NS; Maestá I; Fülöp V; Braga A; Elias KM
    Gynecol Oncol; 2023 Mar; 170():114-122. PubMed ID: 36682089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there uniformity in definitions and treatment of gestational trophoblastic disease in Europe?
    Frijstein MM; Lok CAR; Coulter J; van Trommel NE; Ten Kate-Booij MJ; Golfier F; Seckl MJ; Massuger LFAG
    Int J Gynecol Cancer; 2019 Jan; 29(1):108-112. PubMed ID: 30640691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia.
    Baptista AM; Belfort P
    Int J Gynaecol Obstet; 2012 Oct; 119(1):35-8. PubMed ID: 22877838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate.
    Gilani MM; Fariba B; Behtash N; Ghaemmaghami F; Moosavi AS; Rezayof E
    J Cancer Res Ther; 2013; 9(1):38-43. PubMed ID: 23575072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
    Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
    Lurain JR; Schink JC
    J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The added value of hysterectomy in the management of gestational trophoblastic neoplasia.
    Eysbouts YK; Massuger LFAG; IntHout J; Lok CAR; Sweep FCGJ; Ottevanger PB
    Gynecol Oncol; 2017 Jun; 145(3):536-542. PubMed ID: 28390821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.